Back ICAAC 2009

ICAAC 2009

ICAAC 2009: Raltegravir (Isentress) plus Atazanavir (Reyataz) Maintenance Therapy Appears Safe and Effective in Small Study

A dual maintenance regimen consisting of the recently approved integrase inhibitor raltegravir (Isentress) plus the protease inhibitor atazanavir (Reyataz) was well tolerated and kept viral load below 50 copies/mL in more than 80% of patients with no prior history of treatment failure, according to a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) last month in San Francisco.

Read more:

ICAAC 2009: People Who Decline Routine HIV Testing Are More Likely to Be Positive, Written Consent Requirement May Discourage Testing

People who "opted out" of routine HIV testing in a Washington, DC, emergency department were almost 3 times more likely to be infected than those who accepted voluntary testing, according to a poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) last month in San Francisco. Another study suggested that requiring written informed consent may cause more people to decline testing.

Read more:

New Injectable Drug Peramivir Is as Effective as Oseltamivir (Tamiflu) for Seasonal Influenza

A single intravenous injection of the new flu drug peramivir worked as well as the widely used oral agent oseltamivir (Tamiflu) for relieving symptoms of seasonal influenza, according to 2 presentations at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) last week in San Francisco. While these studies did not involve the novel H1N1 "swine" flu, peramivir works the same way as agents that are active against the new virus. alt

Read more:

ICAAC 2009: Nevirapine (Viramune) and Boosted Atazanavir (Reyataz) Produce Comparable Early Virological and Immunological Response

Early virological response has been proposed as a marker of efficacy of antiretroviral therapy (ART). In the ARTEN trial, nevirapine (Viramune) showed similar efficacy to ritonavir-boosted atazanavir (Reyataz), but with a more favorable lipid profile after 48 weeks. Results from a sub-analysis of the ARTEN trial looking at early virological and immunological response were presented last week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) in San Francisco last week.

Read more:

ICAAC 2009: Tobacco and Marijuana May Significantly Lower Atazanavir (Reyataz) Blood Levels

Use of tobacco and marijuana reduced trough (lowest level between doses) blood concentrations of the protease inhibitor atazanavir (Reyataz), although the effects of alcohol, cocaine, and opiates such as heroin did not reach statistical significance, according to a poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) this week in San Francisco.

alt

Read more: